Abstract: Prodrugs of nicotinic acid which include ribosyl groups are provided. The compounds and pharmaceutical compositions thereof may be used to treat or prevent to treat or prevent a variety of medical disorders, which are characterized by mitochondrial dysfunction such as, for example, metabolic disorders, cardiovascular disorders, cerebrovascular disorders, liver disorders, kidney disorders or muscle disorders.

Abstract: The disclosure relates to in vivo and ex vivo uses of dihydronicotinamide riboside (NRH), dihydronicotinic acid riboside (NARH) and reduced derivatives thereof to treat immune-related disorders (e.g., systemic inflammatory response syndrome and sepsis), kidney disorders (e.g., acute kidney injury and hepatorenal syndrome [HRS]), liver disorders (e.g., acute liver failure and HRS), hemolytic disorders (e.g., hemolysis and hemolytic anemia), and disorders and conditions associated with oxidative stress, damage or injury (e.g., methemoglobinemia and anemia). NRH, NARH and reduced derivatives thereof can be used in vivo or ex vivo alone or in combination with one or more additional therapeutic agents, such as an anti-inflammatory agent or/and an antioxidant.

Abstract: The present disclosure relates to a method of treating non-alcoholic steatohepatitis (NASH) comprising administering to a subject with NASH a combination therapy comprising semaglutide, firsocostat, and/or cilofexor.

Abstract: Disclosed are novel prodrugs derived from nicotinic acid and pharmaceutical compositions thereof which may be used to treat or prevent a variety of medical disorders, which may be characterized by mitochondrial dysfunction. The compounds and pharmaceutical compositions thereof may be used to treat or prevent metabolic disorders, cardiovascular disorders, cerebrovascular disorders, liver disorders, a kidney disorders or muscle disorders.

Abstract: Provided are methods for treating hepatitis B virus infections by administering a NS5A inhibitor, NS5B inhibitor, a NS3 inhibitor, or combinations thereof.

Abstract: The disclosure provides nicotinamide riboside (NR), the reduced form of NR (NRH), nicotinic acid riboside (NAR), the reduced form of NAR (NARH), derivatives thereof, compositions thereof and uses thereof. The NR and NAR derivatives have improved stability and bioavailability compared to NR and NAR. NR, NRH, NAR, NARH, and derivatives thereof can increase cellular NAD+ levels and enhance mitochondrial and cellular function and cell viability. Therefore, NR, NRH, NAR, NARH, and derivatives thereof, whether alone or in combination with one or more additional therapeutic agents (e.g., a mitochondrial uncoupler or/and a PARP inhibitor), are useful for treating mitochondrial diseases, mitochondria-related diseases and conditions, metabolic disorders, and other disorders and conditions.

Abstract: The disclosure relates to in vivo and ex vivo uses of dihydronicotinamide riboside (NRH), dihydronicotinic acid riboside (NARH) and reduced derivatives thereof to treat immune-related disorders (e.g., systemic inflammatory response syndrome and sepsis), kidney disorders (e.g., acute kidney injury and hepatorenal syndrome [HRS]), liver disorders (e.g., acute liver failure and HRS), hemolytic disorders (e.g., hemolysis and hemolytic anemia), and disorders and conditions associated with oxidative stress, damage or injury (e.g., methemoglobinemia and anemia). NRH, NARH and reduced derivatives thereof can be used in vivo or ex vivo alone or in combination with one or more additional therapeutic agents, such as an anti-inflammatory agent or/and an antioxidant.

Abstract: Provided are methods for treating hepatitis B virus infections by administering a NS5A inhibitor, NS5B3 inhibitor, a NS3 inhibitor, or combinations thereof.

Abstract: The present disclosure relates to a method of treating non-alcoholic steatohepatitis (NASH) comprising administering to a subject with NASH a combination therapy comprising semaglutide, firsocostat, and/or cilofexor.

Abstract: The disclosure provides nicotinamide riboside (NR), the reduced form of NR (NRH), nicotinic acid riboside (NAR), the reduced form of NAR (NARH), derivatives thereof, compositions thereof and uses thereof. The NR and NAR derivatives have improved stability and bioavailability compared to NR and NAR. NR, NRH, NAR, NARH, and derivatives thereof can increase cellular NAD+ levels and enhance mitochondrial and cellular function and cell viability. Therefore, NR, NRH, NAR, NARH, and derivatives thereof, whether alone or in combination with one or more additional therapeutic agents (e.g., a mitochondrial uncoupler or/and a PARP inhibitor), are useful for treating mitochondrial diseases, mitochondria-related diseases and conditions, metabolic disorders, and other disorders and conditions.

Abstract: Methods for detecting network model data errors are disclosed. In some examples, methods for detecting network model data errors may include splitting a network model into a first plurality of portions, executing an algorithm on each of the portions, identifying a portion for which the algorithm is determined to be non-converged, splitting the identified portion into a second plurality of portions, repeating the executing, identifying and splitting the identified portion until a resulting identified portion is smaller than a predefined threshold, and examining the resulting identified portion to identify plausible data errors therein. In some examples, examining the resulting identified portion to identify plausible data errors therein may include executing a modified algorithm, which may include an augmented measurement set, on the identified portion.

Abstract: The teachings herein disclose an advantageous method and apparatus for performing Security Constrained Economic Dispatch (SCED) for a hybrid power system that includes one or more AC grids interconnected with one or more multi-terminal High Voltage DC (HVDC) grids. The teachings include optimizing a non-linear objective function, subject to a set of constraints that include AC and DC grid constraints, for determining the SCED solution using successive linear approximation. The linear programming model used in the linear approximations is advantageously augmented with a DC grid portion in a manner that accounts for the effects of the DC grid on the AC grid, but which does not require exposing proprietary DC grid modeling details, and which conforms the resultant SCED solution to all applicable AC and DC grid constraints, including AC grid line flow constraints, AC grid power balance constraints, DC grid line flow constraints, and DC grid power balance constraints.

Abstract: Methods of treating hepatitis C virus infection in a subject with cirrhosis comprising administering to the subject an effective amount of Compound 1.

Abstract: The teachings herein disclose an advantageous method and apparatus for performing Security Constrained Economic Dispatch (SCED) for a hybrid power system that includes one or more AC grids interconnected with one or more multi-terminal High Voltage DC (HVDC) grids. The teachings include optimizing a non-linear objective function, subject to a set of constraints that include AC and DC grid constraints, for determining the SCED solution using successive linear approximation. The linear programming model used in the linear approximations is advantageously augmented with a DC grid portion in a manner that accounts for the effects of the DC grid on the AC grid, but which does not require exposing proprietary DC grid modeling details, and which conforms the resultant SCED solution to all applicable AC and DC grid constraints, including AC grid line flow constraints, AC grid power balance constraints, DC grid line flow constraints, and DC grid power balance constraints.

Abstract: This application describes methods of preventing, treating or reducing the risk of recurrence of a hepatitis C virus infection in a subject after the subject has received a liver transplant. Disclosed herein are methods of preventing or reducing the risk of recurrence of a hepatitis C virus infection in a subject after the subject has received a liver transplant, the methods comprising administering to the subject an effective amount of Compound 1. Also disclosed are methods of reducing HCV RNA levels to about 25 IU/mL or lower in a subject having received a liver transplant comprising administering to the subject an effective amount of Compound 1.

Abstract: Methods for detecting network model data errors are disclosed. In some examples, methods for detecting network model data errors may include splitting a network model into a first plurality of portions, executing an algorithm on each of the portions, identifying a portion for which the algorithm is determined to be non-converged, splitting the identified portion into a second plurality of portions, repeating the executing, identifying and splitting the identified portion until a resulting identified portion is smaller than a predefined threshold, and examining the resulting identified portion to identify plausible data errors therein. In some examples, examining the resulting identified portion to identify plausible data errors therein may include executing a modified algorithm, which may include an augmented measurement set, on the identified portion.

Abstract: The invention provides methods employing iterative cycles of recombination and selection/screening for evolution of whole cells and organisms toward acquisition of desired properties. Examples of such properties include enhanced recombinogenicity, genome copy number, and capacity for expression and/or secretion of proteins and secondary metabolites.

Abstract: The invention provides methods employing iterative cycles of recombination and selection/screening for evolution of whole cells and organisms toward acquisition of desired properties. Examples of such properties include enhanced recombinogenicity, genome copy number, and capacity for expression and/or secretion of proteins and secondary metabolites.

Abstract: The system integrates a business rule engine with an engineering application that performs one or more predetermine functions relating to the monitoring, analyzing or controlling of a physical system. Rule processing requests are transmitted from the engineering application to a rule based service which manages the data retrieval, data insertion, rule engine invocation activities in a two pass design so as to optimize the rule processing performance for online system monitoring and control.

Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.